Effect and safety on carteorol for infantile hemangioma
Phase 2
- Conditions
- infantile hemangioma
- Registration Number
- JPRN-UMIN000029988
- Lead Sponsor
- Takatsuki General Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1 congenital hemangioma, Kasabah-Merritt syndrome 2 hypoglycemia, hypotension, bradycardia (arrhythmia), cardiac function disorder 3 Otehr drug administaraion interacted with carteorol within 14 days 4 history of other therapy foy infantile hemangioma(steroid therapy, laser therapy etc)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method